Pfizer Inc. (PFE) - Quarterly EPS earnings growth

Pfizer Inc. possesses colossal authority in medicine due to the creation of life-saving vaccines. This reputation supports revenue stability, although reliance on patents forces the company to acquire startups. This quarterly EPS chart clearly confirms these processes, where the parameter value reaches -8.90. Currently, management under Albert Bourla is optimizing expenses to restore investor confidence in the post-pandemic period.

pfizer.com (PFE) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/10/2026

Analytical breakdowns for Pfizer Corp (PFE)

- share price and expert price forecast:

Stock Price Pfizer|PFE - Broker Consensus Forecast

- market capitalization indicators:

Market Capitalization Pfizer Corporation|PFE - Company Buyout Price

- balance sheet net asset value indicators:

Net Assets per Single Share Pfizer|PFE - Accounting Capitalization|Market Capitalization to Book Value Ratio pfizer.com|PFE - Company Balance Sheet Assets

- debt level and financial liquidity data:

- earnings and market multiples details:

PFE - Company Net Income|Expected Profit Pfizer Inc.|PFE - Company Value to Net Income|Projected Price to Earnings Pfizer Corporation|PFE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Pfizer Corporation|PFE - Operating income before deduction of amortization|Earnings per share for the last twelve months Pfizer|PFE - Earnings per share for the last 12 months|Quarterly EPS earnings growth pfizer.com|PFE - Net earnings per share growth this year|Expected earnings per share growth for next year Pfizer Inc.

General company analysis:Pfizer - PFE

This indicator measures the quarterly change in earnings per share, reflecting the business's capitalization rate. The effective combination of in-house substance synthesis and outsourced clinical trials directly impacts this calculation. By analyzing the quarterly shift in earnings per share, an investor can see the actual speed of value generation. Growth in this metric confirms the resilience of the Pfizer Inc. (PFE) operating model, serving as a signal regarding the quality of capital allocation.

Competitors of Pfizer Inc. (PFE)

LLY: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ABBV|AZN (AstraZeneca AB) - Quarterly EPS earnings growth|Novartis Pharma (NVS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Merck & Co., Inc. (MRK)|novonordisk.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth AMGN (Amgen)|Net earnings per share growth for the trailing year Sanofi SA|BMY - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months GSK|TAK: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months TEVA (Teva)|RDY (Dr. Reddy's) - Quarterly EPS earnings growth|Viatris Inc (VTRS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ROIV (Roivant Sciences Ltd)|ZLAB: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth BHC (Bausch Health Companies)|cosmosholdingsinc.com (COSM) - Earnings per share growth in annualized terms for the last twelve months